{
  "extraction_metadata": {
    "timestamp": "2025-10-01T17:05:18.079746",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 10,
    "temperature": 0.3
  },
  "outcomes_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "Outcomes": "overall survival (OS), all-cause mortality, time to progression (TTP), progression-free survival (PFS), recurrence-free survival, disease control rate (DCR; defined as complete response, partial response, or stable disease maintained for at least 28 days according to RECIST), tumor response rate, objective response rate (ORR), duration of response (DoR), tumor reduction, local recurrence, local control, length of hospital stay (LOS), days of missed work, adverse events (general), serious adverse events (SAEs), complication incidence, major complications, hand-foot syndrome, diarrhoea, diarrhea, fatigue, rash, skin rash, desquamation, hypertension, pain, fever, nausea, vomiting, myelosuppression, liver failure, post-treatment complications, post-TACE syndromes, cognitive functioning (health-related quality of life dimension), body image (EORTC QLQ-HCC18 functional scale), nutrition (EORTC QLQ-HCC18 functional scale), sex life (EORTC QLQ-HCC18 functional scale), symptoms (EORTC QLQ-C30 symptom scales), health status, health-related quality of life, EORTC QLQ-C30, EORTC QLQ-HCC18, time to deterioration (EORTC QLQ-C30 and EORTC QLQ-HCC18; defined as a score increase by at least 10 points over baseline), length of hospital stay, liver function, economic outcomes (quality-adjusted life years, cost-effectiveness, incremental cost-effectiveness ratio, ICER)",
      "ChunksUsed": 25,
      "ContextTokens": 8985
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "Outcomes": "all-cause mortality, overall survival (OS), time to progression (TTP), disease control rate (DCR; defined as the percentage of patients who had a complete response, a partial response or stable disease according to RECIST maintained for at least 28 days after the first demonstration of that rating), tumor response rate, overall response rate (ORR), tumor reduction, recurrence-free survival, progression-free survival (PFS), disease progression, local recurrence, local control, length of hospital stay (LOS), days of missed work, adverse events, serious adverse events (SAEs), hand-foot syndrome, hand-foot skin reaction, diarrhoea, diarrhea, fatigue, rash, skin rash, skin rash or desquamation, hypertension, pain, fever, nausea, vomiting, myelosuppression, liver failure, post-treatment complications, post-TACE syndromes (pain, fever, nausea, vomiting), cognitive functioning (health-related quality of life dimension), body image (EORTC QLQ-HCC18 functional scale), nutrition (EORTC QLQ-HCC18 functional scale), sex life (EORTC QLQ-HCC18 functional scale), role functioning (EORTC QLQ-C30 functional scale), symptoms (EORTC QLQ-C30 symptom scales), health status, liver function, complications, EORTC QLQ-C30, EORTC QLQ-HCC18, time to deterioration (EORTC QLQ-C30 and EORTC QLQ-HCC18; defined as a score increase by at least 10 points over baseline), quality of life, health-related quality of life",
      "ChunksUsed": 25,
      "ContextTokens": 8773
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "Outcomes": "overall survival (OS), progression-free survival (PFS; RECIST 1.1), time to progression (TTP), objective response rate (ORR), complete response (CR), partial response (PR), duration of response (DoR), time to response, disease control rate (DCR; mRECIST), clinical benefit rate (CBR), health-related quality of life (HRQoL), EORTC QLQ-C30, EORTC QLQ-HCC18, EQ-5D, EQ-5D visual analogue scale (VAS), EQ-5D health utility index (HUI), time-to-symptom worsening (TSW; EORTC QLQ-C30, EORTC QLQ-HCC18, EQ-5D VAS, EQ-5D HUI), pain (EORTC QLQ-C30 domain), diarrhoea (EORTC QLQ-C30 domain), nutrition (EORTC QLQ-HCC18 domain), body image (EORTC QLQ-HCC18 domain), adverse events (general), serious adverse events, adverse events leading to discontinuation, pharmacokinetics (PK), plasma pharmacokinetics exposure parameters, PK/PD relationship between exposure and efficacy/safety, economic outcomes (cost-effectiveness, quality-adjusted life years, QALYs)",
      "ChunksUsed": 25,
      "ContextTokens": 10220
    },
    "EN": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EN",
      "Outcomes": "overall survival, time to radiological disease progression, time to symptomatic disease progression (FHSI-8 questionnaire), diarrhoea, hand-foot skin reaction, dermatological toxicities, hypertension, haemorrhage, cardiac ischaemia, cardiac infarction, gastrointestinal perforation, hepatic impairment, wound healing complications, quality-adjusted life years (QALYs), cost-effectiveness (incremental cost-effectiveness ratio, ICER), adverse events (general), resource use, palliative care, treatment duration",
      "ChunksUsed": 25,
      "ContextTokens": 7781
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "Outcomes": "overall survival (OS; time from randomisation to death from any cause), progression-free survival (PFS; time from randomisation to tumour progression defined by RECIST 1.1 or death from any cause), objective response rate (ORR; percentage of patients with partial or complete response, RECIST 1.1), objective response rate (ORR; percentage of patients with partial or complete response, mRECIST), duration of response (DoR; time from partial or complete response to disease progression or exit), deterioration in patient quality of life (based on EORTC QLQ-C30), deterioration in patient quality of life (based on EORTC QLQ-HCC18), time to patient-reported impairment of quality of life (EORTC QLQ-C30), time to patient-reported impairment of quality of life (EORTC QLQ-HCC18), time to patient-reported impairment of quality of life (EORTC QLQ-C30 functional role subscale), time to patient-reported impairment of quality of life (EORTC QLQ-C30 fitness subscale), serious adverse events, adverse events (general), gastrointestinal disorders, bleeding, infections, liver disorders, hypothyroidism, infusion reactions, hyperthyroidism, hypertension, proteinuria, immuno-mediated hepatitis, fatigue, increased aspartate aminotransferase (AST), pruritus, diarrhoea, fever, loss of appetite, increased alanine aminotransferase (ALT), constipation, increased serum bilirubin, abdominal pain, nausea, cough, thrombocytopenia, weight loss, epilepsy, palmar rash, asthenia, diabetes mellitus, hand-foot syndrome, arterial hypertension, neutropenia, hyporexia, need for hospital medical day (HDM), intrahospital administration, outpatient regimen, ambulatory regimen",
      "ChunksUsed": 20,
      "ContextTokens": 7274
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), progression-free survival (PFS; RECIST 1.1), time to progression, objective response rate (ORR), disease control rate, clinical benefit rate, quality of life (EQ-5D-3L), EORTC QLQ-C30, EORTC QLQ-HCC18, adverse events (general), serious adverse events, grade 3 adverse reactions, treatment-related deaths, hepatotoxicity, hypertension, loss of appetite, weight loss, haemorrhagic events, thromboembolic events, hypothyroidism, hepatic encephalopathy, hepatic insufficiency, decreased appetite, arterial thromboembolic events, renal events, proteinuria, hand-foot syndrome, dysphonia, alopecia, fatigue, encephalopathies, increased bilirubin, abdominal pain, sepsis, brain haemorrhage, brain/gastrointestinal bleeding, intestinal failure, respiratory failure, cerebral vascular accident, cardiovascular arrest, myocardial infarction, sudden death, ascites, tumour progression, QTc interval prolongation, hypocalcaemia, hyperthyroidism, gastrointestinal perforations, gastrointestinal fistulas, non-gastrointestinal fistulas, venous thromboembolic events, renal failure, cardiac insufficiency",
      "ChunksUsed": 25,
      "ContextTokens": 8429
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "Outcomes": "overall survival, time to symptom progression, time to progression, disease control, partial response, minor response (reduction of tumour size by 25 to 50%), stable disease (for at least 16 weeks), fatigue, bleeding, abdominal pain, hypertension (grade 3/4), diarrhoea (grade 3/4), lymphoedema (grade 3/4), abdominal pain (grade 3/4), hand feeding reactions (grade 3/4), serious adverse reactions, adverse reactions (general), cost-effectiveness analysis, cost",
      "ChunksUsed": 15,
      "ContextTokens": 4512
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), complete response (CR), partial response (PR), stable disease (SD), disease control rate (DCR), infections, lymphopenia, anorexia, hypophosphataemia, haemorrhage, hypertension, diarrhoea, nausea, vomiting, constipation, dry skin, rash, alopecia, hand-foot skin reaction, erythema, pruritus, arthralgia, fatigue, pain, fever, decreased weight, increased amylase, increased lipase, folliculitis, leukopenia, neutropenia, anaemia, thrombocytopenia, hypothyroidism, hypocalcaemia, hypokalaemia, hyponatraemia, hypoglycaemia, depression, peripheral sensory neuropathy, dysgeusia, tinnitus, congestive heart failure, myocardial ischaemia, myocardial infarction, flushing, rhinorrhoea, dysphonia, stomatitis, dyspepsia, dysphagia, gastro-oesophageal reflux disease, keratoacanthoma, squamous cell cancer of the skin, dermatitis exfoliative, acne, skin desquamation, hyperkeratosis, myalgia, muscle spasms, renal failure, proteinuria, erectile dysfunction, asthenia, influenza like illness, mucosal inflammation, transient increase in transaminases, hand-foot skin reaction (grade 3 or 4), rash or skin desquamation (grade 3 or 4), weight loss (grade 3 or 4), decreased appetite (grade 3 or 4), increased ALT activity (grade 3 or 4), adverse events (general), FACT-G (Functional Assessment of Cancer Therapy – General), EQ-5D (Euro QoL – 5 dimensions), EQ VAS (Euro QoL visual analogue scale), quality-adjusted life years (QALYs), cost-effectiveness (incremental cost-effectiveness ratio, ICER), number needed to treat (NNT), number needed to harm (NNH)",
      "ChunksUsed": 25,
      "ContextTokens": 8028
    },
    "PT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PT",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), quality of life, pharmacokinetic parameters, vital signs, laboratory haematological testing, laboratory biochemical testing, urinalysis, electrocardiography, adverse events (graded according to the National Cancer Institute), major adverse events, Grade 3 adverse reactions, Grade 4 adverse reactions, treatment-related mortality, dropout rate for critical toxicity, EORTC QLQ-C30, EORTC QLQ-HCC18, cost minimisation analysis",
      "ChunksUsed": 10,
      "ContextTokens": 3267
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "Outcomes": "overall survival (OS, time from randomization to death from any cause), progression-free survival (PFS), objective tumour response, time to tumour progression, duration of treatment (TTD), adverse reactions leading to discontinuation of treatment, adverse events (general), grade 3 or higher adverse reactions, EQ-5D-5L, EQ-5D-3L, quality-adjusted life years (QALYs), cost-effectiveness (cost-benefit analysis, cost comparison, incremental cost-effectiveness ratio, ICER)",
      "ChunksUsed": 25,
      "ContextTokens": 8759
    }
  }
}